No insider purchase over the last 90 days. The latest was filed 22 Jun 2026.
Alvotech S.A. is a listed company. Its directors and officers file their transactions with Nasdaq Baltic. The last twelve months, up to 18 October 2026, brought 9 filings signed by 4 insiders.
Purchases and sales both appear in the filings: 6 purchases (4 insiders, €1) and 3 sales (2 insiders, €1). The totals do not cover 7 filings with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Biggest ticket of the year: €1, sold by Celtic Lux Holdings S.a. r.l. and made public on 3 July 2026 (0.0000% of market cap).
The last insider purchase was made public on 22 June 2026, 117 days ago. The median gap between a trade and its publication by Nasdaq Baltic is 7 days. For comparison, MAR article 19 gives managers three business days to notify a trade.
The full history, which starts in 2023, counts 19 purchases against 7 sales.
These figures are compiled from regulatory filings published by Nasdaq Baltic. They describe what insiders did and are not a recommendation.
+3 other insiders
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
25 of 26 declarations
Alvotech S.A. is a company focused on the development of biosimilar drugs. It is listed on the XICE market.